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A B S T R A C T
Liposarcomas are rare malignant tumors of adipocytic differentiation. The classiﬁcation of liposarcomas
into four principal subtypes reﬂects the distinct clinical behavior, treatment sensitivity, and underlying
biology encompassed by these diseases. Increasingly, clinical management decisions and the devel-
opment of investigational therapeutics are informed by an improved understanding of subtype-speciﬁc
molecular pathology. Well-differentiated liposarcoma is the most common subtype and is associated
with indolent behavior, local recurrence, and insensitivity to radiotherapy and chemotherapy. Dedif-
ferentiated liposarcoma represents focal progression of well-differentiated disease into a more ag-
gressive, metastasizing, and fatal malignancy. Both of these subtypes are characterized by recurrent
ampliﬁcationswithin chromosome12, resulting in the overexpression of disease-driving genes that have
been the focus of therapeutic targeting. Myxoid liposarcoma is characterized by a pathognomonic
chromosomal translocation that results in an oncogenic fusion protein, whereas pleomorphic lip-
osarcoma is a karyotypically complex and especially poor-prognosis subtype that accounts for less than
10% of liposarcoma diagnoses. A range of novel pharmaceutical agents that aim to target liposarcoma-
speciﬁc biology are under active investigation and offer hope of adding to the limited available treatment
options for recurrent or inoperable disease.
J Clin Oncol 35. © 2017 by American Society of Clinical Oncology. Licensed under the Creative
Commons Attribution 4.0 License: http://creativecommons.org/licenses/by/4.0/
INTRODUCTION
Liposarcomas (LPSs) are malignant tumors of
adipocytic differentiation. They are among the more
common soft tissue sarcoma (STS) subtypes, ac-
counting for approximately 15% to 20%of all STSs.1
This disease is classiﬁed into four principal subtypes:
well-differentiated LPS (WDLPS; also known as
atypical lipomatous tumor), dedifferentiated LPS
(DDLPS), myxoid LPS (MLPS), and pleomorphic
LPS (PLPS; Table 1).2 An improved appreciation of
the contrasting clinical behaviors of these subtypes,
coupled with a growing understanding of their un-
derlying molecular pathology, has led to increasingly
subtype-tailored management and the development
of novel systemic therapies. In this article, we review
the key clinical, pathologic, and molecular charac-
teristics of the LPS subtypes, summarize current
management, and provide an overview of ongoing
investigation of new therapeutic strategies.
LPS SUBTYPES
WDLPS and DDLPS
WDLPS and DDLPS together account for the
majority of LPSs and often coexist (WD/DDLPS).
WDLPS can present as slowly growing masses in
the retroperitoneum and proximal extremities. Dis-
tinguishing between peripheral WDLPS and much
more commonly encountered benign adipocytic
neoplasms may be challenging—lesions that are
. 5cm in diameter, rapidly growing, and/or
deep to superﬁcial fascia warrant specialist
evaluation. WDLPSs have no metastatic potential
and are associated with an excellent outcome when
complete excision is achieved. Local recurrence is
more common when WDLPS arises in the retro-
peritoneum, mediastinum, or paratesticular region3
and is a cause of morbidity and mortality, as is the
emergence of dedifferentiated disease. DDLPS is
a high-grade and aggressive disease, arising most
commonly within the retroperitoneum, and is
associated with high rates of local and metastatic
recurrence and disease-speciﬁc mortality that is
six-fold that of WDLPS.4 Both WDLPS and DDLPS
are typically radioinsensitive and chemoinsensitive.5
Sharedmorphologic andmolecular features indicate
that DDLPS occurs as a focal outgrowth within
precursor WDLPS lesions, with 90% of DDLPS
found within a primary WDLPS lesion and 10%
within areas of locally recurrent WDLPS6 (Fig 1).
Histologically,WDLPS appears as a proliferation
of mature and variably pleomorphic adipocytes
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intersected by ﬁbrous septa and containing single, enlarged,
hyperchromatic nuclei (Fig 2A). DDLPS is characterized by more
highly cellular areas of high-grade undifferentiated sarcoma typically
transitioning abruptly within a background of WDLPS (Fig 2B).
Supernumerary ring or giant rod chromosomes are found in both
WDLPS and DDLPS. These consist of ampliﬁed segments of 12q13-
15 that contain a number of cancer-related genes implicated in
tumorigenesis.7 Themost extensively studied of these areMDM2, an
E3 ubiquitin protein ligase that acts as a key negative regulator of p53
and is ampliﬁed in nearly 100% of patients, and cyclin-dependent
Table 1. Clinical and Pathologic Features of the Four Principle Liposarcoma Subtypes
Liposarcoma Subtype Well-Differentiated Dedifferentiated Myxoid Pleomorphic
Estimated proportion
of liposarcoma (%)
40-50 15-20 20-30 5-10
Age of peak incidence
(years)
50-60 50-60 30-50; can occur in childhood/
adolescence
$ 50
Typical morphology Proliferation of pleomorphic
mature adipocytes, variable
numbers of lipoblasts present
High-grade pleomorphic sarcoma
on well-differentiated
background
Round/oval mesenchymal cells
plus signet ring lipoblasts
within myxoid stroma
Variable number of pleomorphic
lipoblasts on background of
high-grade pleomorphic
sarcoma
Typical sites of origin Extremities Retroperitoneum Thigh; other proximal extremities Lower limb
Retroperitoneum Extremities Upper limb
Paratesticular (rare) Paratesticular
Mediastinum (rare) Mediastinum
Head and neck
Patterns of
recurrence
Local recurrence
(retroperitoneum .
extremities)
Local recurrence in approximately
40%
Local and/or metastatic (bone,
soft tissue, serosa) in up to
40%
Local recurrence in 30%-50%
Little to no metastatic potential Metastasis (lung) in approximtely
20%-30%
Metastasis (lung) in 30%-50%
Response to available
therapies
Poor Poor Typically sensitive to radiotherapy
and chemotherapy
Variable chemosensitivity
Genomics 12q13-15 ampliﬁcation 12q13-15 ampliﬁcation plus other
chromosomal abnormalities
t(12;16) with FUS-DDIT3 fusion Complex, with multiple
chromosomal abnormalities
and higher mutation rate
Fig 1. Radiologic appearance of retroperi-
toneal well-differentiated/dedifferentiated lip-
osarcoma. Sagittal and coronal precontrast
computed tomography images of a large
liposarcoma expanding the retroperitoneum
and encasing and displacing the left kidney.
The blue arrow denotes a well-differentiated
tumor, which shares a similar appearance to
normal fat, extending inferiorly to the pelvic
brim. The red arrow denotes a complex, ill-
deﬁned solid component of mixed attenua-
tion, representing an area of dedifferentiated
disease superior to left kidney.
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kinase 4 (CDK4), a key regulator of the G1/S cell cycle checkpoint
that is coampliﬁed with MDM2 in over 90% of patients8 (Fig 2C).
Other genes commonly coampliﬁed within the 12q13-15 amplicon
includeHMG2A, encoding an architectural transcription factor shown
to be capable of cellular transformation, and TSPAN31, a gene of
currently unknown function that has been shown to be ampliﬁed
in multiple STS subtypes.9,10 YEATS4 and CPM are genes com-
monly coampliﬁed within 12q13-15 that have been implicated in
dedifferentiation.11,12 YEATS4 is a putative transcription factor
required for physiologic suppression of p53 function and is im-
plicated in oncogenesis across a number of cancers. In a large-scale
genomic screening study of DDLPS cells, YEATS4 knockdown con-
ferred greater antiproliferative effect than loss of MDM2 expression.11
CPM encodes carboxypeptidase M, a proteolytic enzyme with roles
that include cleavage activation of growth factors, including epidermal
growth factor. In a study of 12q-ampliﬁed LPS cell lines and xeno-
grafts,CPM knockout resulted in inhibition of growth, migration, and
invasion, in association with downregulation of MAPK and PI3K
pathway signaling.12
Although the somatic mutation rate has been shown to be low
in WDLPS and DDLPS, the accumulation of additional chro-
mosomal abnormalities seems to be central to the development of
DDLPS.11,12 Recurrent ampliﬁcations of 1p32 and 6q23 are found
exclusively in DDLPS and are associated with a worse prognosis.13
Overexpression of ASK1 (found in 6q23) and JUN (1p32) has been
implicated in dedifferentiation through mechanisms that involve in-
hibition of peroxisomeproliferator-activated receptor gamma, (PPARg),
a key mediator of adipocyte differentiation.14,15 LPS genomic proﬁling
studies have also identiﬁed chromosomal deletions of tumor suppressor
genes such as RB1 (13q14.2), ATM, and CHEK1 (both 11q22-24), and
RUNX3 andARID1A (both 1p36), that variably demonstrate association
with reduced adipocytic differentiation, increased genomic instability,
and worse clinical outcome.11,12 A potential role for receptor tyrosine
kinase–mediated oncogenicity is suggested by the identiﬁcation in
DDLPS cell lines and clinical samples of chromosomal amplicons
that contain DDR2, ERBB3, FGFR1, and ROS1.16
Myxoid LPS
MLPS accounts for approximately 30% of LPSs and is clin-
ically and pathologically distinct from WD/DDLPS.2 Over 90% of
MLPSs contain a pathognomonic t(12;16)(q13;p11) translocation
that results in expression of the FUS-DDIT3 fusion protein, whereas
a smaller proportion carries EWSR1-DDIT3 gene fusions.17 Mi-
croscopically, MLPS has small, round-to-oval, nonadipocytic mes-
enchymal tumor cells alongside a variable number of immature
lipoblasts on a background of prominent myxoid stroma (Fig 2D).
Round cell LPS is now recognized as a high-grade, more cellular
variant of MLPS that is associated with worse outcomes2,18 (Fig 2E).
MLPS typically develops in the proximal extremities, with two thirds
A B C
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Fig 2. Histologic appearance of liposarcoma subtypes. (A) Hematoxylin and eosin stain ofwell-differentiated liposarcoma (3 40). Tumor is composed ofmature adipocytes in
normal adipose tissue prominently intersected by sparsely cellular ﬁbrous septa containing atypical, enlarged spindle cells with hyperchromatic nuclei. (B) Dedifferentiated
liposarcoma (3 200). Hematoxylin and eosin stain illustrates typical appearance of dedifferentiated component as a high-grade spindle or pleomorphic sarcoma, with sheets of
moderately atypical spindle cells with scattered mitotic ﬁgures and no apparent adipocytic differentiation. (C) Immunohistochemistry staining of dedifferentiated liposarcoma
(3 40) shows diffuse and strong expression of CDK4, frequently coampliﬁed with MDM2 in well-differentiated and dedifferentiated liposarcoma. (D) Myxoid liposarcoma
(3 200). Relatively bland and uniform appearance,with small ovoid or spindle cells dispersed in prominentmyxoid stroma alongside plexiform network of curvilinear, thin-walled
blood vessels. In many areas, small lipoblasts with nuclear indentation and vacuolated cytoplasm are identiﬁable (arrows). (E) Round cell variant of myxoid liposarcoma (3 40).
Markedly cellular distribution of round and ovoid cells containing rounded, hyperchromatic nuclei andminimal, largely amphophilic cytoplasm. As in this example, the absence of
discernible myxoid stroma can lead to round cell myxoid liposarcoma being mistaken for other round cell neoplasms such as Ewing sarcoma. (F) Pleomorphic liposarcoma
(3 200). Large, atypical multivacuolated lipoblasts with indented hyperchromatic nuclei are dispersed in a background of atypical spindle cells.
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of cases originating in the thigh (Fig 3). Local recurrence and me-
tastasis to atypical sites such as bone, retroperitoneum, serosal surfaces,
and/or contralateral limb are commonly encountered. In addition to
an increased round cell component, higher histologic grade, multi-
focality, and overexpression of p53 have been associated with an
adverse prognosis.18,19 MLPSs are markedly more chemosensitive and
radiosensitive than WD/DDLPSs.5
The FUS-DDIT3 fusionprotein is believed to confer tumorigenicity
in MLPS through dysregulation of adipocyte differentiation, leading to
unchecked proliferation of immature lipoblasts that are incapable of
differentiating.20 FUS is an FET family protein involved in regulation of
transcription and RNA splicing, whereas DDIT3 is a member of the C/
EBP transcription factor family that plays a role in adipocyte differ-
entiation.21 Variant translocations, such as t(12;22)(q13;q12), resulting
in fusion of EWS, another FET family member, to DDIT3, are likely to
have similar mechanisms of oncogenesis.
Gene expression studies of MLPS have identiﬁed recurrent upre-
gulation ofMET, RET, and PIK3CA, indicating that these oncogenes may
be under downstream transcriptional control by fusion proteins.22 Ac-
tivating mutations or ampliﬁcation of PIK3CA are seen in approximately
15% of MLPS, whereas PTEN deletion has also been described.11,23
Pleomorphic LPS
PLPS is a rare and clinically aggressive LPS subtype. Typically
arising in the limbs or, less commonly, the trunk or retroperitoneum,
PLPS histologically appears as a high-grade undifferentiated sarcoma
without recognizable lineage and contains a variable number of
pleomorphic lipoblasts (Fig 2F). Distant metastases develop in 30% to
50% of patients, typically involving the lungs, and are generally un-
responsive to chemotherapy or radiotherapy.24,25 Tumor-associated
mortality occurs in up to 50% of patients.26
Current understanding of the molecular pathology of PLPS is
limited. Characteristically, PLPSs have complex karyotypes consisting
of multiple chromosomal losses and gains, indicating pathogenesis
driven by complex and variable molecular events.21 Deletion of
13q14.2-5 (containing RB1) has been described in up to 50% of
patients.11,27 Mutation or loss of TP53 is also seen, in contrast to
other forms of LPS where TP53 alteration is uncommon.11 Loss of
the tumor suppressor gene NF1 is exhibited in a proportion of pa-
tients, whereas epigenetic silencing of the p53 target gene p14ARF has
been implicated as playing a role in tumorigenesis.12,28
CURRENT MANAGEMENT
Localized Disease
Wide local excision with clear surgical margins is the core
curative treatment in localized LPS. The optimal extent of resection
for retroperitoneal LPS is unresolved, with some authors advo-
cating more extensive resection as a means of reducing high rates
of local recurrence.29 Patients with deep-seated, high-grade LPS
A B
C
Fig 3. Radiologic appearance of myxoid
liposarcoma of the proximal thigh. (A) Coronal
T2-weighted magnetic resonance image of
80-mm tumor (arrow) with characteristic high
signal intensity. T1-weighted fat-suppressed
axial magnetic resonance images of (B) pre-
gadolinium and (C) postgadolinium contrast
show avid and heterogeneous enhancement
of tumor (arrow).
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arising in the extremities should be offered adjuvant or neo-
adjuvant radiotherapy in line with randomized data for extremity
STS.30 The addition of perioperative radiotherapy to the manage-
ment of localized retroperitoneal STS has been reported to produce
favorable rates of local recurrence in noncomparative series.31 The
role of neoadjuvant radiotherapy for high-risk, operable retroperi-
toneal STS should be deﬁned by the results of the now-completed
Phase III Randomized Study of Preoperative Radiotherapy Plus Sur-
gery Versus Surgery Alone for Patients With Retroperitoneal Sarcoma
(STRASS) trial (NCT01344018).
Although the role of systemic therapy in early-stage STS remains
contentious, the greater chemosensitivity of MLPS may indicate
a role for adjuvant chemotherapy in this subtype. A single-arm trial of
preoperative trabectedin in locally advanced MLPS showed a path-
ologic complete response in three of 23 assessable patients and partial
radiologic response in seven of 29 evaluable patients.32 A recent phase
III trial comparing neoadjuvant epirubicin-ifosfamide with subtype-
tailored chemotherapy in high-risk, localized STS has suggested
similar efﬁcacy between trabectedin in MLPS and the more toxic
combination regimen.33
Decisions regarding surgical and perioperative management
of retroperitoneal LPS should be considered on a case-by-case basis
within a specialist multidisciplinary team. Such decisions should
balance the speciﬁcs of tumor anatomy and subtype biology with
aggressive upfront strategies.
Advanced Disease
The development of unresectable local and/or metastatic LPS
is associated with a poor prognosis. Similar to other STS subtypes,
standard ﬁrst-line therapy consists of anthracycline-based sched-
ules.34 In the European Organization for Research and Treatment
of Cancer (EORTC) 62012 phase III trial, post hoc subgroup analysis
indicated no improvement in response rate or overall survival (OS) in
patients with LPS treated with combination doxorubicin-ifosfamide
compared with doxorubicin alone.35 LPS-speciﬁc efﬁcacy data are
currently unavailable for olaratumab, a PDGFRA-targeting mono-
clonal antibody recently approved in combination with doxorubicin
for untreated advanced STS on the basis of improved OS compared
with doxorubicin alone in a randomized phase II trial36. Meanwhile,
there is clinical evidence that LPS subtypes have differential sensitivity
to other available systemic therapies (Table 2).
Trabectedin is approved for pretreated, advanced LPS on the
basis of randomized evidence of improved progression-free sur-
vival compared with dacarbazine.39,44 Trabectedin is a DNA minor
groove binder that also binds to and inhibits the FUS-DDIT3 fusion
protein, reversing the blockage of adipocytic differentiation and
inhibiting growth in MLPS preclinical models.45 This effect is
reﬂected by clinical evidence of pronounced effect of trabectedin
against MLPS in randomized studies.38,40,41
In a randomized phase III trial of patients with previously
treated advanced LPS or leiomyosarcoma, OS was signiﬁcantly su-
perior in patients who received eribulin, a microtubule inhibitor,
compared with standard dacarbazine (HR, 0.768; 95% CI, 0.618 to
0.954; P = .017).42 Preplanned subgroup analysis indicated that the
beneﬁt of eribulin was largely restricted to patients with LPS (HR,
0.51; 95%CI, 0.35 to 0.75; P= .006), resulting in approval of the drug
in this disease group only.37
A single-arm phase II trial of the multitarget tyrosine kinase
inhibitor (TKI) pazopanib in advanced STS showed that the drug
was inactive in the LPS subgroup, leading to the exclusion of this
subtype from the subsequent phase III trial.46,47 The differential
sensitivity of LPS subtypes to pazopanib has been evaluated in two
trials (NCT01506596, NCT01692496). Other multitarget TKIs,
including sunitinib, sorafenib, and regorafenib, have shown little
indication of efﬁcacy in LPS.43,48,49
INVESTIGATIONAL THERAPIES
Given the frequency and apparent oncogenic role of MDM2 and
CDK4 overexpression in WD/DDLPS, there has been signiﬁcant
effort to target these proteins therapeutically.
MDM2 Antagonists
A number of drugs of different chemical classes have been
shown in LPS preclinical models to bind to MDM2 and disrupt its
interaction with p53, resulting in upregulation of p53-mediated
effects, such as cell cycle arrest and apoptosis.50-53 Functional
nonmutated p53 seems to be necessary for the anticancer effect of
such drugs51. In a proof-of-mechanism study of the nutlin-3a-derived
drug RG7112 in operable WD/DDLPS, one partial response was seen
in 20 treated patients, with best response of stable disease in 14
patients and progression in ﬁve.54 Comparison of pretreatment and
post-treatment tumor samples showed up to a three-fold increase in
p53 and p21 expression, with associated increases in tumor apoptosis.
Signiﬁcant neutropenia and thrombocytopenia were among the re-
ported toxicities.
In a ﬁrst-in-human phase I trial of SAR405838, a spiro-
oxinodole inhibitor of MDM2, 49 evaluable patients with LPS
were treated.55 No objective responses were recorded, but disease
stabilization was seen in 32 patients (65%), with an associated
3-month progression-free rate (PFR) of 32%. Thrombocytopenia
was the dose-limiting toxicity with a daily dosing schedule, whereas
no dose-limiting toxicity was reached with a weekly regimen. In
a translational substudy, sequencing of sequential circulating cell-free
tumor DNA demonstrated that increases in burden of radiologically
apparent disease correlated with increasing levels of peripherally
detectable TP53 mutation.56 These data implicate clonal outgrowth
of TP53-mutated tumor as a potential mechanism of resistance to
MDM2 inhibition.
MK-8242 is a small molecule inhibitor of MDM2, with phase I
data showing partial responses in three of 42 treated patients with LPS
(7%) and stable disease in 31 (74%).57 Additional MDM2 inhibitors
of several other classes, including DS-3032B, CGM097, and JNJ-
26854165, are under ongoing investigation.
CDK4 Inhibitors
Palbociclib is an inhibitor of CDK4 and CDK6 that is ap-
proved for advanced breast cancer and has been shown to induce
cell cycle arrest in CDK4-overexpressing LPS cells.11 In a single-
arm phase II study of palbociclib, 48 patients with WD/DDLPS
were treated with a dosage of 200 mg once daily for 14 days every
3 weeks.58 CDK4 was ampliﬁed in 92% of patients, whereas pRb
expression was intact in 85% of tumors. At this initial dosing level,
jco.org © 2017 by American Society of Clinical Oncology 5
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signiﬁcant hematologic toxicity, along with one partial response
and a 12-week PFR of 66%, was seen. An additional 30 patients with
WD/DDLPS were then treated at a lower-dose schedule of 125 mg
once per day for 21 days every 4 weeks. In these patients, the 12-week
PFR was 57%, with one radiologic complete response and reduced
toxicity compared with the original dosing.
Ribociclib is another CDK4/6 inhibitor currently being investigated
in WD/DDLPS (NCT03096912). In a phase I trial of ribociclib in LPS,
no objective responses were observed (0 of 39 evaluable patients), al-
though disease stabilization surpassing 6months was seen in six patients
(15%).59 Toxicities included neutropenia and QTc prolongation.
Other CDK4/6 inhibitors, including the structurally distinct
abemaciclib that is able to cross the blood-brain barrier,60 are cur-
rently under clinical investigation in WD/DDLPS as single agents or
in combination with MDM2 or mTOR inhibitors (NCT02846987,
NCT02343172, NCT03114527). Preclinical studies have indicated
that intact baseline expression of ATRX and demonstrable loss of
MDM2 expression after treatment seem to be necessary for CDK4
inhibition to successfully induce cancer cell senescence.61 The po-
tential utility of ATRX expression as a biomarker for CDK4/6 in-
hibitors has yet to be clinically tested.
Exportin 1 Inhibitors
Exportin 1 (XPO1) is a known mediator of the nuclear export
of more than 200 proteins, many of which have tumor suppressor
functions. XPO1 overexpression is seen in multiple cancer types,
including LPS. Knockdown of XPO1 function in LPS cells induced
apoptosis and inhibited tumor growth in LPS xenografts, with
treated cells exhibiting upregulation of adipocyte differentiation-
related genes and reduced mitosis-related gene expression.62 Seli-
nexor, a selective inhibitor of XPO1, was investigated in a phase IA/IB
trial in patients with advanced cancer with recently conﬁrmed disease
progression, including 19 with DDLPS.63 In 15 evaluable patients
with DDLPS, no objective responses were seen, but disease stabili-
zation . 4 months was recorded in seven patients (47%), six of
whom had a reduction in the target lesion size that did not reach
partial response criteria. Recurring grade 3 adverse events included
fatigue, anemia, and thrombocytopenia. A placebo-controlled phase
II/III trial on DDLPS is now recruiting (NCT02606461).
PPARg Agonists
PPARg is a nuclear receptor that regulates the transcription of
genes that are critical for terminal adipocyte differentiation. LPS
cells are induced to differentiate in vitro on PPARg agonist exposure.64
Although repurposing PPARg agonists used to treat diabetes pro-
duced disappointing phase II results in LPS,65,66 more recent phase I
results with efatutazone, a third-generation thiazolidinedione PPARg
agonist, were more encouraging, with partial response sustained at
23 months in one patient with MLPS.67 A single-arm phase II trial of
efatutazone in advanced MLPS is ongoing (NCT02249949).
Immunotherapy
In the Sarcoma Alliance for Research Through Collaboration
(SARC) 028 phase II study of pembrolizumab in advanced STS,
two of 10 patients treated for DDLPS met partial disease response
criteria.68 Meanwhile, high expression of the cancer testis antigen
NY-ESO-1 has been shown in a large proportion of MLPS patients.69
Therapeutic targeting of this antigen with peptide vaccine or adoptive
cell therapies is currently under way and has been associated with
some early encouraging pharmacodynamic and clinical results.70,71
Other Investigational Agents
Sitravatinib (MGCD516) is a TKI active against a broad
spectrum of targets, including MET, PDGFRA, c-Kit, and IGF-1R,
and is currently under phase II investigation in patients with LPS
(NCT02978859). In preclinical work, sitravatinib demonstrated
superior antiproliferative effects over other TKIs across a range of
STS cell lines and xenografts, including IGF-1R–overexpressing LPS
models.72 Phase I data showed mucositis, fatigue, and neuropathy as
dose-limiting toxicities.
Aurora kinase A (AURKA) is a critical mediator ofmitosis that is
commonly overexpressed in STS.11 Alisertib, an inhibitor of AURKA,
exhibits in vitro antiproliferative effects against LPS cells73 and was
associated with a 73% 12-week progression-free rate in 12 patients
with LPS treated within a phase II study of the drug.74 There has yet
to be additional clinical development of AURKA inhibitors in LPS.
A repurposing phase I/II of the anti-HIV protease inhibitor
nelﬁnavir in LPS showed disappointing clinical efﬁcacy signal despite
compelling in vitro data demonstrating the induction of cell cycle
arrest and apoptosis in DDLPS cells by the drug via upregulation of
SREBP-1, an adipocyte differentiation-related transcription factor.75,76
In conclusion, LPS encompasses a number of different subtypes
with distinct underlying biology and clinical behavior. Additional work
is required to better understand subtype-speciﬁc biology and to
identify new targets. A recent randomized trial has suggested that
neoadjuvant trabectedinmay have similar activity to anthracycline and
ifosfamide in localized myxoid LPS. Furthermore, two randomized
phase III trials have led to the approval of trabectedin and eribulin for
advanced pretreated LPS. Despite this, there is a clear need for further
development of subtype-speciﬁc therapy in LPS. MDM2 and CDK4
inhibitors have shown some evidence of efﬁcacy in WD/DDLPS, but
also toxicity. The precise role of these agents remains to be deﬁned,
particularly the potential for combination therapy. A number of other
promising agents are currently being evaluated in advanced LPS, and
the results of these ongoing trials are eagerly awaited. Ongoing national
and international collaboration is critical to coordinate research efforts
and quickly establish the efﬁcacy of trialed agents while ensuring that
high-quality translational research is performed.
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